SCHEMBL26014178

SCHEMBL26014178

N[C@@H](CCCCNC(=O)N1CCN(CCO)CC1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.48
DRD3 P35462 6/20 0.48
HTT P42858 1/20 0.44
OTC P00480 1/20 0.40
GSR P00390 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
FAAH O00519 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39
MAPK1 P28482 1/20 0.39
MTOR P42345 1/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25358690 1.00 DRD2 (0.48) DRD2DRD3HTTOTCGSR
SCHEMBL1768790 0.90 HTT (0.47) DRD2DRD3HTTCA12CA1
SCHEMBL13585586 0.90 HTT (0.47) DRD2DRD3HTTCA12CA1
SCHEMBL26009119 0.87 OTC (0.38) DRD2DRD3HTTOTCGSR
SCHEMBL25360385 0.86 DRD2 (0.44) DRD2DRD3HTTOTCGSR
SCHEMBL26009122 0.86 DRD2 (0.44) DRD2DRD3HTTOTCGSR
SCHEMBL25359229 0.85 DRD2 (0.43) DRD2DRD3OTCGSRTPSAB1
SCHEMBL25357414 0.85 DRD2 (0.43) DRD2DRD3OTCGSRTPSAB1
SCHEMBL26009500 0.85 DRD2 (0.43) DRD2DRD3OTCGSRTPSAB1
SCHEMBL25358822 0.84 DRD2 (0.42) DRD2DRD3OTCGSRTPSAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 EP disclosed
EP-4724459-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Peptidream Inc (JP) 2026-04-15 EP disclosed
WO-2024254339-A9 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2025-10-16 WO disclosed
WO-2024254339-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2024-12-12 WO disclosed
WO-2024252336-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF PEPTIDREAM INC. (JP) 2024-12-12 WO disclosed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP DRD2 3504/4885DRD3 3493/4885HTT 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.